The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Gedeon Richter PlcEU/1/21/1565/001-002

Main Information

Trade NameRyeqo
Active SubstancesRelugolix
Estradiol hemihydrate
Norethisterone acetate
Dosage FormFilm-coated tablet
Licence HolderGedeon Richter Plc
Licence NumberEU/1/21/1565/001-002

Group Information

H01CC54 Relugolix, estradiol and norethisterone


License statusAuthorised
Licence Issued16/07/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back